Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening

• Status: Withdrawn
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate Suprep bowel preparation, with and without the anti-gas medication simethicone, in terms of efficacy and patient tolerability in the preparation of patients undergoing routine colonoscopy for colorectal cancer screening.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mercy Medical Center, Des Moines, Iowa; MercyOne Des Moines Medical Center
• Treatments: Cathartics; Magnesium Sulfate; Pharmaceutical Solutions; Simethicone; Sodium sulfate

Criteria

Inclusion Criteria:

• Age greater than 18 years

• Outpatients who require elective colonoscopy for colorectal cancer screening at Iowa Endoscopy Center and at University of Florida - Jacksonville

Exclusion Criteria:

• Allergy or hypersensitivity to any constituent of the lavage solution or to simethicone

• Presence of any contraindication to colonoscopy (i.e. uncontrolled congestive heart failure, New York Heart Association classification III-IV, history of myocardial infarction within 6 months, coagulopathy)

• Massive ascites

• Renal insufficiency

• Pregnancy

• History of colonic surgery

• History of anti-flatulence or laxative agent within one week

• Refusal/inability to give consent

• Patients undergoing colonoscopy for reasons other than colorectal cancer screening

• Mentally disabled

• Non-English-speaking patients